Shares of the Dutch biotech Pharming jumped on the news that the FDA had put its transgenic therapy for angioedema on a fast-track review process. Investors saw the move as a key strategic victory for rhC1INH, which is derived from the milk of genetically altered rabbits. Pharming is competing with Jerini to gain approval for a new treatment for angioedema, which is characterized by a swelling of body tissue. After years of experiments and trials, transgenics has made some big gains in recent months. Most notably, GTC Biotherapeutics won the endorsement of ATryn--a therapy derived from goat milk--from a key European advisory council.

- read the AFX report on Pharming

ALSO: Here's a feature on GTC's progress with ATryn. Article